The early infiltration by leukocytes into the tumor microenvironment leads to neovascularization, enhanced tumor growth, metastasis and lethality of the host. Notably, leukocytes enable tumor establishment, as suggested early on by Virchow in 1826 and proven more recently by others (e.g. Manning et al, 2007 Clin Ca Res 13:3951;review Wasiuk/Noelle et al. 2009 Clin Exp Immunol 155:140). Our own preliminary data (Noelle et al.) show that if one interferes with the early infiltration of inhibitory leukocytes, one can greatly enhance the development of protective tumor immunity and survival of the host. Further, eradicating mast cells increases survival from 5% to over 80% of mice to immunogenic tumors. In lieu of eradicating mast cells, our studies have evaluated if anti-tumor immunity can be enhanced by blocking angiogenesis. The preliminary data show that the use of anti-VEGFR2 Ab, which is functionally equivalent to the eradication of mast cells, can similarly increase survival of the host to immunogenic tumors. The premise of this proposal is that tumor vaccines that induce immunity to a non-immunogenic tumor like B16 melanoma, require an anti-angiogenic/mast cell approach to ensure that tumor site inhibitory leukocytes do not inhibit otherwise highly effective tumor-specific cell mediated immunity (CMI), as well as a cytoreduction/chemotherapeutic agent to provide immunologic space for effective CMI to develop. While most anti-angiogenesis studies focus directly on tumor site vasculature, investigators have begun to evaluate the impact of blocking angiogenesis on host responses to tumors. Based on our studies and those published, we hypothesize that anti-angiogenic factors will greatly enhance the efficacy of our tumor vaccine to elicit superior protective, acquired, tumor-specific cell-mediated immunity. In Aim 1 we propose to use our experience in developing melanoma vaccines to provide proof-of-concept for a combination vaccine that 1) uses our proprietary CD40/TLR agonist adjuvant vaccine to induce superior CMI against tumors relative to vaccine technologies currently used by others, and 2) broadly abrogates angiogenesis/mast cell-induced inhibition of CMI across several additional tumor models. Furthermore, in Aim 2, cytoreductive/chemotherapy methods, shown to be somewhat effective in the clinic, will be overlaid on this approach to test for additional efficacy.
Public Health Relevance: The premise of this proposal is that tumor vaccines that induce immunity to poorly or non-immunogenic tumors like B16 melanoma, require an anti-angiogenic/mast cell approach plus cytoreductive chemotherapy to ensure that the tumor site does not inhibit otherwise highly effective anti-tumor leukocytes. The approach here, based on our preliminary results, is to develop a combination therapy using our proprietary anti-CD40/TLR adjuvant vaccine combined with blocking Ab to the angiogenesis factor VEGFR2 as well as the cytoreductive chemotherapeutic Cytoxan. We predict that we can improve anti-tumor immunity against a range of otherwise hard-to-treat tumor states.
Thesaurus Terms: 2h-1,3,2-Oxazaphosphorin-2-Amine, N,N-Bis(2-Chloroethyl)Tetrahydro-, 2-Oxide;2h-1,3,2-Oxazaphosphorin-2-Amine, N,N-Is(2-Chloroethyl)Tetrahydro-,2-Oxide;Adjuvant;Agonist;Angiogenesis Antagonists;Angiogenesis Blockers;Angiogenesis Inhibitors;Angiogenetic Antagonists;Angiogenic Antagonists;Angiogenic Factor;Angiogenic Switch;Angiostatic Agents;Anti-Angiogenesis;Anti-Angiogenetic Agents;Anti-Angiogenic Agents;Anti-Angiogenic Drugs;Antiangiogenesis;Antiangiogenesis Agents;Antiangiogenic Agents;Antineoplastic Vaccine;Ascaridil;Autologous;B Cell Lymphoma;B Lymphoma;B-Cell Lymphomas;B-Cell Non-Hodgkin's Lymphoma;B-Cell Nonhodgkins Lymphoma;Basophilic Histiocyte;Basophils, Tissue;Blood Leukocyte;Bp50;Cd40;Cdw40;Ctx;Cyclo-Cell;Cancer Cause;Cancer Etiology;Cancer Vaccines;Carcinoma Of Ovary;Carcinoma Of Bladder;Carcinoma Of The Urinary Bladder;Carloxan;Cell Mediated Immunology;Cell-Mediated Immunity;Cells;Cellular Immunity;Chemosensitization;Chemosensitization/Potentiation;Ciclofosfamida;Ciclofosfamide;Cicloxal;Clafen;Claphene;Clinic;Clinical;Combined Modality Therapy;Combined Vaccines;Cycloblastin;Cycloblastine;Cyclophospham;Cyclophosphamide;Cyclophosphamidum;Cyclophosphan;Cyclophosphane;Cyclophosphanum;Cyclostin;Cyclostine;Cytophosphan;Cytophosphane;Cytoxan;Dna Synthesis Factor;Data;Decaris;Development;Ecgf;Effector Cell;Endothelial Cell Growth Factor;Endoxan;Endoxana;Enduxan;Ensure;Ergamisol;Ergamisole;Fgf;Factor, Angiogenesis;Fetal Liver Kinase-1;Fibroblast Growth Factor;Fibroblast Growth Regulatory Factor;Flk-1 Protein;Flk-1 Receptor Tyrosine Kinase;Fosfaseron;Generalized Growth;Genoxal;Genuxal;Goals;Growth;Hbgf;Health;Immune;Immune Response;Immune System;Immunity;Immunity, Cellular;Immunol;Immunologic, Immunochemical;Immunologics;Infiltration;Inhibitors, Angiogenetic;Inhibitors, Angiogenic;Investigators;Kdr Tyrosine Kinase;Ketrax;Kinase Insert Domain Receptor;Ledoxina;Leukocytes;Mgc9013;Malignant Melanoma;Mammals, Mice;Marrow Mast Cell;Marrow Leukocyte;Mast Cell Neoplasm;Mast Cell Proliferative Disease;Mastocytoma;Melanoma Vaccine;Metastasis;Metastasize;Metastatic Neoplasm;Metastatic Tumor;Methods;Mice;Mitoxan;Modality;Modeling;Multimodal Therapy;Multimodal Treatment;Multimodality Treatment;Murine;Mus;Myelogenous;Myeloid;Neoplasm Metastasis;Neosar;Neovascularization Inhibitors;Oncogenesis;Ovarian Carcinoma;Play;Potentiation;Process;Procytox;Production;Programs (Pt);Programs [publication Type];Protocol;Protocols Documentation;Protocols, Treatment;Publishing;Rgm;Receptor Protein;Regimen;Regulatory T-Lymphocyte;Relative;Relative (Related Person);Research Personnel;Researchers;Reticuloendothelial System, Leukocytes;Secondary Neoplasm;Secondary Tumor;Sendoxan;Site;Solaskil;Study Models;Suppressor Cells;Suppressor-Effector T-Lymphocytes;Syklofosfamid;T Suppressor Cell;T-Cells, Suppressor-Effector;T-Lymphocytes, Suppressor-Effector;Tnfrsf5;Tnfrsf5 Gene;Technology;Testing;Therapeutic;Therapy, Vaccine;Time;Tissue Growth;Tramisol;Treatment Protocols;Treatment Regimen;Treatment Schedule;Trimisol;Tumor Angiogenesis;Tumor Antigens;Tumor Burden;Tumor Cell;Tumor Cell Migration;Tumor Immunity;Tumor Load;Tumor Necrosis Factor Receptor Superfamily Member 5 Gene;Tumor Of The Mast Cells;Tumor-Associated Antigen;Vac-Tx;Vegf Receptor Flk-1;Vegf Receptor Kdr;Vegfr-2;Vegfr2;Vegfs;Vaccination;Vaccine Adjuvant;Vaccine Antigen;Vaccine Design;Vaccine Therapy;Vaccines;Vaccines, Combination;Vaccines, Combined;Vaccines, Neoplasm;Vaccines, Tumor;Vascular Endothelial Growth Factor Receptor-2;Vascular Endothelial Growth Factors;Vegf;White Blood Cells;White Cell;Wound Healing;Wound Repair;Zytoxan;Acquired Immunity;Angiogenesis;Angiogenesis Factor;Antiangiogenesis Therapy;Antiangiogenic;Base;Bladder Carcinoma;Body System, Allergic/Immunologic;Cancer Metastasis;Cellular Immunity;Chemotherapeutic Agent;Chemotherapy;Clinical Relevance;Clinically Relevant;Combination Therapy;Combined Modality Treatment;Combined Treatment;Experience;Host Response;Immunogenic;Immunoresponse;Improved;Mast Cell;Mastocyte;Melanoma;Model;Multimodality Therapy;Neoplastic Cell;Neovascularization;Ontogeny;Organ System, Allergic/Immunologic;P50;Programs;Receptor;Response;Suppressor T Lymphocyte;Tissue Repair;Tumor;Tumor Growth;Tumor-Specific Antigen;Tumorigenesis;Vaccine-Induced Immunity;White Blood Cell;White Blood Corpuscle
